Cocrystal Pharma (COCP) Cost of Revenue (2010 - 2013)

Cocrystal Pharma has reported Cost of Revenue for 4 years, with the latest figure at $1.4 million in Q2 2013.

• Quarterly Cost of Revenue fell 51.27% year-over-year to $1.4 million in Q2 2013, while the trailing twelve-month figure through Jun 2013 was $7.9 million (down 31.63% YoY) and the FY2012 annual result came in at $10.0 million, changed 0.5% from the prior year.
• Cost of Revenue fell to $1.4 million in Q2 2013 per COCP's latest filing, from $1.4 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $4.7 million in Q4 2011 and troughed at $138088.0 in Q1 2011.
• A 4-year average of $2.2 million and a median of $2.1 million in 2012 frame the typical range for Cost of Revenue.
• The widest YoY moves for Cost of Revenue: up 1395.34% in 2012, down 54.32% in 2012.
• Over 4 years, Cost of Revenue stood at $2.9 million in 2010, then soared by 63.96% to $4.7 million in 2011, then tumbled by 54.32% to $2.2 million in 2012, then sank by 34.73% to $1.4 million in 2013.
• According to Business Quant data, Cost of Revenue over the past three periods registered $1.4 million, $1.4 million, and $2.2 million for Q2 2013, Q1 2013, and Q4 2012 respectively.